½ÃÀ庸°í¼­
»óǰÄÚµå
1516051

¼¼°èÀÇ Ç÷û ºÐ¸® °Ö ½ÃÀå : Á¦Ç°º°, ÃÖÁ¾ ¿ëµµº°, ¿¹Ãø(2024-2032³â)

Serum Separation Gel Market - By Product (Serum Separation Gel Without Integrated Tubes, Serum Separation Gel with Integrated Tubes), End-use (Hospitals, Blood Banks, Pharmaceutical Companies)- Global Forecast (2024 - 2032)

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Global Market Insights Inc. | ÆäÀÌÁö Á¤º¸: ¿µ¹® 130 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°è Ç÷û ºÐ¸® °Ö ½ÃÀåÀº 2024³âºÎÅÍ 2032³â±îÁö ¿¬Æò±Õ 5.9%ÀÇ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÀÌ·¯ÇÑ ¼ºÀåÀº ÀÇ·á ½ÇÇè½Ç¿¡¼­ È¿À²ÀûÀÌ°í ½Å·ÚÇÒ ¼ö ÀÖ´Â Áø´Ü µµ±¸¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿¡ µû¸¥ °ÍÀÔ´Ï´Ù. Ç÷û ºÐ¸® °ÖÀº Áø´Ü °Ë»ç¿¡ Áß¿äÇÑ Ç÷¾× ºÐ¸®ÀÇ Á¤È®¼º°ú Á¤¹Ðµµ¿¡ Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. ¿¹¸¦ µé¾î, ¿À¼ÒÄÚÆÛ·¹À̼ÇÀº 2023³â 8¿ù ¾ß¸¶±¸Ä¡Çö ½´³­½Ã¿¡ À§Ä¡ÇÑ ºÐ¸® Á¤Á¦ °øÀå¿¡¼­ TOYOPEARL-TSKgel PW »ç¾÷À» Àü°³ÇÒ °èȹÀ̶ó°í ¹ßÇ¥Çß½À´Ï´Ù. ÀÌ °áÁ¤Àº Á¤È­ ¼ö¿ä Áõ°¡¿¡ ´ëÀÀÇϱâ À§ÇÑ °ÍÀÔ´Ï´Ù.

ȸ»çµéÀº È¿À²¼ºÀ» ³ôÀÌ°í ¼¼°è ¼ö¿ä Áõ°¡¿¡ ´ëÀÀÇϱâ À§ÇØ Ã·´Ü Á¦Á¶ Àåºñ¿Í ½Å±â¼ú¿¡ ¸¹Àº ÅõÀÚ¸¦ Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¸¸¼º ÁúȯÀÇ Áõ°¡¿Í Á¤±âÀûÀÎ °Ç°­ °ËÁøÀÇ Çʿ伺ÀÌ ½ÃÀå ¼ö¿ä¸¦ ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ±× °á°ú, Ç÷û ºÐ¸® °Ö ½ÃÀåÀº ÷´Ü ±â¼ú ¹ßÀü°ú Àü·«Àû ÀÎÇÁ¶ó¿¡ ÈûÀÔ¾î °­·ÂÇÑ ¼ºÀå¼¼¸¦ º¸À̰í ÀÖ½À´Ï´Ù.

ÀÏüÇü Æ©ºê°¡ ¾ø´Â Ç÷û ºÐ¸® °Ö ºÎ¹®Àº ÀÓ»ó ¿¬±¸ ȯ°æ¿¡¼­ °£´ÜÇÏ°í ºñ¿ë È¿À²ÀûÀÎ ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¿ä±¸·Î ÀÎÇØ 2024³âºÎÅÍ 2032³â±îÁö °­·ÂÇÑ ¼ºÀå¼¼¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ, ºÐ¼® Á¤È®µµ¿Í ¸ðµ¨¸µ È¿À²¼º¿¡ ´ëÇÑ ¿ä±¸°¡ ³ô¾ÆÁö¸é¼­ Áø´Ü¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ´Â °Íµµ ÀÌ·¯ÇÑ ¼ö¿ä¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ±× °á°ú, Á¦Á¶¾÷üµéÀº ÀÏüÇü Àåºñ¸¦ »ç¿ëÇÏÁö ¾Ê°íµµ Ç÷û ºÐ¸® °ÖÀÇ Ç°Áú°ú °¡¿ë¼ºÀ» Çâ»ó½ÃŰ´Â µ¥ ÁÖ·ÂÇϰí ÀÖ½À´Ï´Ù.

Á¦¾àȸ»ç ºÎ¹®ÀÇ Ç÷û ºÐ¸® °Ö ½ÃÀå Á¡À¯À²Àº 2024³âºÎÅÍ 2032³â±îÁö »ó´çÇÑ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ·¯ÇÑ ¼ºÀåÀº ÀÌ °ÖÀÌ Ç÷¾× Á¤È­¿¡ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÇʼöÀûÀÎ ÀǾàǰ °³¹ß ¹× ÀÓ»ó½ÃÇè¿¡ Á¤È®ÇÏ°í ½Å·ÚÇÒ ¼ö ÀÖ´Â ºÐ¼®À» Á¦°øÇϱ⠶§¹®ÀÔ´Ï´Ù. Á¦¾àȸ»çµéÀº ½Ã·áÀÇ ±ÕÀϼº°ú Àϰü¼ºÀ» º¸ÀåÇϱâ À§ÇØ °íǰÁúÀÇ °Ö ÃßÃâÀ» ÇÊ¿ä·Î ÇÕ´Ï´Ù. ¶ÇÇÑ, °³ÀÎ ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö°í ¸¸¼º ÁúȯÀÇ Áõ°¡·Î ÀÎÇØ ÀÌ·¯ÇÑ ¼ö¿ä°¡ ´õ¿í Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ±× °á°ú Á¦Á¶¾÷ü´Â Á¦¾à »ê¾÷ÀÇ ¿ä±¸¸¦ ÃæÁ·½Ã۱â À§ÇØ »ý»êÀ» ´Ã¸®°í ½ÃÀå ¼ºÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù.

À¯·´ ºÎ¹®ÀÇ Ç÷û ºÐ¸® °Ö ½ÃÀåÀº 2024³âºÎÅÍ 2032³â±îÁö »ó´çÇÑ CAGRÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ´Â ÀÌ Áö¿ªÀÇ ÀÇ·á ÀÎÇÁ¶ó°¡ ºü¸£°Ô °³¼±µÇ°í ÀÖÀ¸¸ç, ÀÏ»óÀûÀÎ ¸ð´ÏÅ͸µÀÌ ÇÊ¿äÇÑ ¸¸¼º ÁúȯÀÇ À¯º´·üÀÌ Áõ°¡Çϰí Àֱ⠶§¹®ÀÔ´Ï´Ù. ¶ÇÇÑ, ½Å·ÚÇÒ ¼ö ÀÖ´Â Ç÷¼ÒÆÇ ºÐ¸® Á¦Ç°¿¡ ´ëÇÑ ¼ö¿ä°¡ »õ·Î¿î ÀÇ·á ±â¼ú¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¾ö°ÝÇÑ ±ÔÁ¦°¡ ÀÌ Áö¿ªÀÇ ½ÃÀå ¼ö¿ä¸¦ ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. Á¦Á¶¾÷üµéÀº ÀÌ·¯ÇÑ ¼ö¿ä Áõ°¡¿¡ ´ëÀÀÇϱâ À§ÇØ »ý»ê·®À» ´Ã¸®°í ÁýÁßÈ­ÇÏ¿© À¯·´ ½ÃÀåÀÇ Áö¼ÓÀûÀÎ ¼ºÀåÀ» º¸ÀåÇϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú Á¶»ç ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ¾÷°è ÀλçÀÌÆ®

  • »ýÅÂ°è ºÐ¼®
  • ¾÷°è¿¡ ´ëÇÑ ¿µÇâ¿äÀÎ
    • ¼ºÀå ÃËÁø¿äÀÎ
      • Áø´Ü °Ë»ç ¼ö¿ä Áõ°¡
      • äÇ÷ ±â¼úÀÇ Áøº¸
      • ¸¸¼ºÁúȯ Áõ°¡
      • POC(Point of Care) °Ë»ç ä¿ë È®´ë
    • ¾÷°èÀÇ ÀáÀçÀû ¸®½ºÅ©¿Í °úÁ¦
      • Ç÷û ºÐ¸® °Ö Æ©ºêÀÇ °íºñ¿ë
      • ±ÔÁ¦ ¿ä°Ç Áؼö
  • ¼ºÀå °¡´É¼º ºÐ¼®
  • ±â¼úÀû Àü¸Á
  • ±ÔÁ¦ »óȲ
  • Porters ºÐ¼®
  • PESTEL ºÐ¼®

Á¦4Àå °æÀï »óȲ

  • ¼Ò°³
  • ±â¾÷ Á¡À¯À² ºÐ¼®
  • °æÀï Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º
  • Àü·« Àü¸Á ¸ÅÆ®¸¯½º

Á¦5Àå ½ÃÀå ÃßÁ¤°ú ¿¹Ãø : Á¦Ç°º°, 2021-2032³â

  • ÁÖ¿ä µ¿Çâ
  • Ç÷û ºÐ¸® °Ö(ÀÏüÇü Æ©ºê ¾øÀ½)
  • Ç÷û ºÐ¸® °Ö(ÀÏüÇü Æ©ºê ÀÖÀ½)

Á¦6Àå ½ÃÀå ÃßÁ¤°ú ¿¹Ãø : ÃÖÁ¾ ¿ëµµº°, 2021-2032³â

  • ÁÖ¿ä µ¿Çâ
  • º´¿ø
  • Ç÷¾×ÀºÇà
  • Á¦¾àȸ»ç
  • ±âŸ

Á¦7Àå ½ÃÀå ÃßÁ¤°ú ¿¹Ãø : Áö¿ªº°, 2021-2032³â

  • ÁÖ¿ä µ¿Çâ
  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • µ¶ÀÏ
    • ¿µ±¹
    • ÇÁ¶û½º
    • ½ºÆäÀÎ
    • ÀÌÅ»¸®¾Æ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ÀϺ»
    • Áß±¹
    • Àεµ
    • È£ÁÖ
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ¾Æ¸£ÇîÆ¼³ª
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • ¾Æ¶ø¿¡¹Ì¸®Æ®
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦8Àå ±â¾÷ °³¿ä

  • Becton, Dickinson and Company
  • BIOSIGMA S.p.A.
  • Bio-Rad Laboratories, Inc.
  • Cardinal Health, Inc.
  • Danaher Corporation
  • FL MEDICAL s.r.l.
  • Greiner AG
  • InterVacTechnology
  • Qiagen N.V.
  • Sekisui Chemical CO., LTD.
ksm 24.07.30

Global Serum Separation Gel Market will observe a CAGR of 5.9% from 2024 to 2032, primarily driven by product expansion from leading companies. These expansions are a response to the growing need for efficient and reliable diagnostic tools in medical laboratories. Serum separation gel plays an important role in the precision and accuracy of blood separation, which is important for diagnostic tests. For example, in August 2023, Osoh Corporation announced the planned dissemination of TOYOPEARL-TSKgel PW operations at their separation refinery located in Shunan, Yamaguchi Prefecture. This decision is in response to the increasing demand for purification.

Companies are investing heavily in advanced manufacturing facilities and new technologies to improve efficiency and meet growing global demand. In addition, the growing prevalence of chronic diseases and the need for regular health check-ups further support the market demand. As a result, the serum isolation gel market is poised for strong growth, supported by leading-edge technological advances and strategic infrastructure.

The overall Serum Separation Gel industry size is classified based on product, end-use application, and region.

The integrated tubeless serum isolation gel segment will grow robustly from 2024 to 2032, driven by the need for simple, cost-effective solutions in clinical research environments. Furthermore, the increasing demand for analytical accuracy and modeling efficiency in diagnostics efforts contributes to this demand. Consequently, manufacturers are focused on increasing the quality and availability of serum separation gels without the use of integrated devices.

The serum separation gel market share from the pharmaceutical company segment will register a notable CAGR from 2024 to 2032. This growth is attributed to the key role this gel plays in blood purification and providing accurate and reliable analysis for essential drug development and clinical trials. Pharmaceutical companies require high-quality gel extraction to ensure sample homogeneity and consistency. In addition, the expanding focus on personalized medicine and the rise of chronic diseases further encourage this demand. Consequently, manufacturers are increasing production to meet the needs of the pharmaceutical industry, leading to market growth.

Serum isolation gel market from the European segment will exhibit a reasonable CAGR from 2024 to 2032. This is due to the rapidly improving healthcare infrastructure in the region, along with the increasing incidence of chronic diseases requiring daily monitoring. Moreover, the need for reliable platelet isolation products drives the demand for new medical technologies. Additionally, stringent regulations are fueling the market demand across the region. Manufacturers are expanding production and centralizing production to meet this growing demand, ensuring continued market growth in Europe.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates & calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising demand for diagnostic testing
      • 3.2.1.2 Growing technological advancement in blood collection
      • 3.2.1.3 Rising prevalence of chronic diseases
      • 3.2.1.4 Growing adoption of point-of-care testing
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 High cost of serum separation gel tubes
      • 3.2.2.2 Compliance with regulatory requirements
  • 3.3 Growth potential analysis
  • 3.4 Technological landscape
  • 3.5 Regulatory landscape
  • 3.6 Porter's analysis
  • 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Competitive positioning matrix
  • 4.4 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Serum separation gel without integrated tubes
  • 5.3 Serum separation gel with integrated tubes

Chapter 6 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Hospitals
  • 6.3 Blood banks
  • 6.4 Pharmaceutical companies
  • 6.5 Other end-users

Chapter 7 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 North America
    • 7.2.1 U.S.
    • 7.2.2 Canada
  • 7.3 Europe
    • 7.3.1 Germany
    • 7.3.2 UK
    • 7.3.3 France
    • 7.3.4 Spain
    • 7.3.5 Italy
    • 7.3.6 Rest of Europe
  • 7.4 Asia Pacific
    • 7.4.1 Japan
    • 7.4.2 China
    • 7.4.3 India
    • 7.4.4 Australia
    • 7.4.5 South Korea
    • 7.4.6 Rest of Asia Pacific
  • 7.5 Latin America
    • 7.5.1 Brazil
    • 7.5.2 Mexico
    • 7.5.3 Argentina
    • 7.5.4 Rest of Latin America
  • 7.6 Middle East and Africa
    • 7.6.1 Saudi Arabia
    • 7.6.2 South Africa
    • 7.6.3 UAE
    • 7.6.4 Rest of Middle East and Africa

Chapter 8 Company Profiles

  • 8.1 Becton, Dickinson and Company
  • 8.2 BIOSIGMA S.p.A.
  • 8.3 Bio-Rad Laboratories, Inc.
  • 8.4 Cardinal Health, Inc.
  • 8.5 Danaher Corporation
  • 8.6 FL MEDICAL s.r.l.
  • 8.7 Greiner AG
  • 8.8 InterVacTechnology
  • 8.9 Qiagen N.V.
  • 8.10 Sekisui Chemical CO., LTD.
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦